{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:23:56Z","timestamp":1783571036987,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bimatoprost ophthalmic solution 0.03% (PGF2\u03b1 analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an effective treatment for vitiligo. To investigate the efficacy and safety of treatment for non-segmental\/segmental vitiligo compared among bimatoprost ophthalmic solution 0.01% combined with NB-UVB phototherapy, bimatoprost monotherapy, and placebo. This single-blind randomized controlled study enrolled stable Thai vitiligo patients with at least three similarly sized lesions in the same anatomical area. The treatment duration was 6\u00a0months with 1- and 2-month post-treatment follow-ups. The 3 selected lesions on each patient were randomized to receive combination therapy, monotherapy, or placebo. The Vitiligo Area Scoring Index (VASI) was used to evaluate lesion response. Of the 25 initially enrolled subjects, 19 patients were analyzed. There were 13 and 6 non-segmental and segmental vitiligo cases, respectively. Eight and 11 cases had face\/neck and non-face\/neck lesions, respectively. Non-segmental vitiligo and non-face\/neck vitiligo patients in the combination group had significant improvement in VASI score at 3\u00a0months, 6\u00a0months, and at the 2-month follow-up. No side effects were observed\/reported. Bimatoprost combination therapy was shown to be safe and effective for treating Thai patients with non-segmental vitiligo in non-face\/neck areas of the body.<\/jats:p>","DOI":"10.1038\/s41598-023-32591-8","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:00:46Z","timestamp":1682002846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study"],"prefix":"10.1038","volume":"13","author":[{"given":"Narumol","family":"Silpa-archa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surachanee","family":"Likittanasombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermkwan","family":"Apinuntham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutipon","family":"Pruksaeakanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norramon","family":"Charoenpipatsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayada","family":"Chaiyabutr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanisada","family":"Wongpraparut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"32591_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","volume":"20","author":"A Ta\u00efeb","year":"2007","unstructured":"Ta\u00efeb, A. & Picardo, M. The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force. Pigment Cell Res. 20, 27\u201335. https:\/\/doi.org\/10.1111\/j.1600-0749.2006.00355.x (2007).","journal-title":"Pigment Cell Res."},{"key":"32591_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jaad.2003.12.044","volume":"51","author":"XJ Zhang","year":"2004","unstructured":"Zhang, X. J. et al. Characteristics of genetic epidemiology and genetic models for vitiligo. J. Am. Acad. Dermatol. 51, 383\u2013390. https:\/\/doi.org\/10.1016\/j.jaad.2003.12.044 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"32591_CR3","first-page":"1219","volume":"148","author":"IC Le Poole","year":"1996","unstructured":"Le Poole, I. C., van den Wijngaard, R. M., Westerhof, W. & Das, P. K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol. 148, 1219\u20131228 (1996).","journal-title":"Am. J. Pathol."},{"key":"32591_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1034\/j.1600-0749.2003.00023.x","volume":"16","author":"K Ongenae","year":"2003","unstructured":"Ongenae, K., Van Geel, N. & Naeyaert, J. M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16, 90\u2013100. https:\/\/doi.org\/10.1034\/j.1600-0749.2003.00023.x (2003).","journal-title":"Pigment Cell Res."},{"key":"32591_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Taieb","year":"2013","unstructured":"Taieb, A. et al. Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br. J. Dermatol. 168, 5\u201319. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11197.x (2013).","journal-title":"Br. J. Dermatol."},{"key":"32591_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1527-3466.2004.tb00134.x","volume":"22","author":"DF Woodward","year":"2004","unstructured":"Woodward, D. F. et al. Bimatoprost: A novel antiglaucoma agent. Cardiovasc. Drug Rev. 22, 103\u2013120. https:\/\/doi.org\/10.1111\/j.1527-3466.2004.tb00134.x (2004).","journal-title":"Cardiovasc. Drug Rev."},{"key":"32591_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi, I. et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: The Vitiligo Area Scoring Index. Arch. Dermatol. 140, 677\u2013683. https:\/\/doi.org\/10.1001\/archderm.140.6.677 (2004).","journal-title":"Arch. Dermatol."},{"key":"32591_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/ijd.12631","volume":"54","author":"TS Anbar","year":"2015","unstructured":"Anbar, T. S., El-Ammawi, T. S., Abdel-Rahman, A. T. & Hanna, M. R. The effect of latanoprost on vitiligo: A preliminary comparative study. Int. J. Dermatol. 54, 587\u2013593. https:\/\/doi.org\/10.1111\/ijd.12631 (2015).","journal-title":"Int. J. Dermatol."},{"key":"32591_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.0022-202X.2004.22516.x","volume":"122","author":"G Scott","year":"2004","unstructured":"Scott, G. et al. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J. Invest. Dermatol. 122, 1214\u20131224. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.22516.x (2004).","journal-title":"J. Invest. Dermatol."},{"key":"32591_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.yexcr.2004.11.016","volume":"304","author":"G Scott","year":"2005","unstructured":"Scott, G. et al. Effects of PGF2alpha on human melanocytes and regulation of the FP receptor by ultraviolet radiation. Exp. Cell Res. 304, 407\u2013416. https:\/\/doi.org\/10.1016\/j.yexcr.2004.11.016 (2005).","journal-title":"Exp. Cell Res."},{"key":"32591_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1468-3083.2009.03346.x","volume":"24","author":"TS Anbar","year":"2010","unstructured":"Anbar, T. S., El-Ammawi, T. S., Barakat, M. & Fawzy, A. Skin pigmentation after NB-UVB and three analogues of prostaglandin F(2alpha) in guinea pigs: A comparative study. J. Eur. Acad. Dermatol. Venereol. 24, 28\u201331. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03346.x (2010).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"32591_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12409","author":"N Bagherani","year":"2017","unstructured":"Bagherani, N. & Smoller, B. R. Efficacy of bimatoprost in the treatment of non-facial vitiligo. Dermatol. Ther. https:\/\/doi.org\/10.1111\/dth.12409 (2017).","journal-title":"Dermatol. Ther."},{"key":"32591_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jocd.12443","volume":"17","author":"AK Jha","year":"2018","unstructured":"Jha, A. K., Prasad, S. & Sinha, R. Bimatoprost ophthalmic solution in facial vitiligo. J. Cosmet. Dermatol. 17, 437\u2013440. https:\/\/doi.org\/10.1111\/jocd.12443 (2018).","journal-title":"J. Cosmet. Dermatol."},{"key":"32591_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/jocd.13648","volume":"20","author":"S Kanokrungsee","year":"2021","unstructured":"Kanokrungsee, S., Pruettivorawongse, D. & Rajatanavin, N. Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study. J. Cosmet. Dermatol. 20, 812\u2013818. https:\/\/doi.org\/10.1111\/jocd.13648 (2021).","journal-title":"J. Cosmet. Dermatol."},{"key":"32591_CR15","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1111\/jdv.14882","volume":"32","author":"S Sharma","year":"2018","unstructured":"Sharma, S., Parsad, D., Bhattacharjee, R. & Muthu, S. K. A prospective right-left comparative study to evaluate the efficacy and tolerability of combination of NB-UVB and topical bimatoprost 0.03% eye drops versus NB-UVB given alone in patients of vitiligo vulgaris. J. Eur. Acad. Dermatol. Venereol. 32, e330\u2013e331. https:\/\/doi.org\/10.1111\/jdv.14882 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"32591_CR16","first-page":"703","volume":"15","author":"PE Grimes","year":"2016","unstructured":"Grimes, P. E. Bimatoprost 0.03% solution for the treatment of nonfacial vitiligo. J. Drugs Dermatol. 15, 703\u2013710 (2016).","journal-title":"J. Drugs Dermatol."},{"key":"32591_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13175","author":"KN Dailami","year":"2020","unstructured":"Dailami, K. N. et al. Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double-blind clinical trial study. Dermatol. Ther. https:\/\/doi.org\/10.1111\/dth.13175 (2020).","journal-title":"Dermatol. Ther."},{"key":"32591_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2008.08923.x","volume":"160","author":"R Kapoor","year":"2009","unstructured":"Kapoor, R., Phiske, M. M. & Jerajani, H. R. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br. J. Dermatol. 160, 861\u2013863. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08923.x (2009).","journal-title":"Br. J. Dermatol."},{"key":"32591_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archopht.123.11.1541","volume":"123","author":"R Kapur","year":"2005","unstructured":"Kapur, R., Osmanovic, S., Toyran, S. & Edward, D. P. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch. Ophthalmol. 123, 1541\u20131546. https:\/\/doi.org\/10.1001\/archopht.123.11.1541 (2005).","journal-title":"Arch. Ophthalmol."},{"key":"32591_CR20","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/jdv.13176","volume":"30","author":"AK Jha","year":"2016","unstructured":"Jha, A. K., Sinha, R., Prasad, S. & Nandan, N. Bimatoprost in periorbital vitiligo: A ray of hope or dilemma. J. Eur. Acad. Dermatol. Venereol. 30, 1247\u20131248. https:\/\/doi.org\/10.1111\/jdv.13176 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32591-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32591-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32591-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:08:50Z","timestamp":1682003330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32591-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32591"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32591-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"28 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6438"}}